Eli Lilly ·
Eli Lilly obtained preliminary injunctions in several of its 2025 compounded tirzepatide cases. Preliminary injunctions are issued early in litigation when the court finds a plaintiff is likely to succeed on the merits, will suffer irreparable harm without relief, and that the balance of equities and public interest favor an injunction. The 2025 injunctions generally restricted defendants from using Lilly's trademarks, from marketing compounded tirzepatide as 'equivalent' or 'generic,' and in some cases from compounding tirzepatide at all pending resolution of the case. These orders significantly reshaped the commercial compounded GLP-1 landscape through 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.